Enliven Therapeutics Directors Rush In: Scott Buys 59k Shares Amid 67% Weekly Rally and Promising Leukemia Trial Results
Enliven Therapeutics’ insider buying spurs optimism after promising Phase 1b results, but investors should stay cautious amid high volatility.
3 minutes to read